The results of phase III clinical trials of Chen Wei's team's new crown vaccine were announced
Last Update: 2021-02-23
Search more information of high quality chemicals, good prices and reliable suppliers, visit
On the evening of February 8th, Yan News () learned from authoritative sources that the mid-stage analysis of China's recombinant new crown vaccine (adenovirus vector) Phase III clinical trial, jointly developed by the
Chen Wei team of the Chinese Academy of Engineering and Concino Bio-Co., Ltd., was successfully completed. Faisal Sultan, Special Assistant to the Prime Minister of Pakistan for Health and Health, announced that in the Phase III clinical trials in Pakistan, the protection effectiveness of the prevention of new crown severe cases after a single dose of the vaccine reached 100 per cent, and the protection effect of the prevention of all new crown cases was 74.8 per cent.
Phase III. clinical trial of the recombined new crown vaccine was first launched in Pakistan on 22 September 2020 and has now been conducted in 78 clinical centres in five countries on three continents, with nearly 50,000 subjects vaccinated. The analysis collected 101 cases from more than 30,000 subjects and showed that the vaccine was safe. The project independent data review
no serious adverse events related to the vaccine will be detected.
reporters learned from authoritative sources that the team in the trial used randomized, double-blind, placebo-controlled design, mainly to assess the effectiveness, safety and immunogenicity of the vaccine in healthy adults 18 years of age and older. The subjects included people over 60 years of age, and the vaccine showed good safety in this population.
the first phase of the vaccine clinical trial on March 16, 2020, involving 108 subjects, and the researchers obtained data on vaccine safety for 7 and 14 days, according to a previous report by The Associated Press. On April 12, Phase II clinical trials were launched with 508 subjects. The vaccine was the only new crown vaccine in the world to enter Phase II clinical trials at the time.
On the evening of July 20, 2020, the international academic journal The Lancet published online a paper on the results of clinical trials of the New Crown Vaccine Phase II (Phase II) developed by Chen Wei, a researcher at the
Military Medical Research Institute of the Chinese Academy of Engineering.
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to email@example.com
. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.